The world's largest pharmacovigilance database — 30 million reports from 170+ countries
VigiBase is the WHO's global database of individual case safety reports, managed by the Uppsala Monitoring Centre (UMC) in Sweden. Established in 1968, it is the world's largest pharmacovigilance database and plays a central role in international vaccine and drug safety monitoring.
Over 30 million individual case safety reports from more than 170 member countries of the WHO Programme for International Drug Monitoring.
Established in 1968 as part of the WHO Programme for International Drug Monitoring. One of the longest-running pharmacovigilance databases in the world.
Operated by the Uppsala Monitoring Centre (UMC), an independent centre collaborating with WHO, based in Uppsala, Sweden.
Summary statistics publicly accessible via VigiAccess at vigibase.who-umc.org. Full individual case data requires institutional access.
A Bayesian statistical measure that compares the observed reporting rate of a drug-event combination to the expected rate based on overall reporting patterns. A high IC value suggests a potential signal worth investigating.
Compares how often a specific adverse event is reported for a given drug versus all other drugs. Used to detect unexpected concentrations of reporting that may indicate a safety signal.
Uppsala Monitoring Centre. "VigiBase." WHO Collaborating Centre for International Drug Monitoring. https://www.who-umc.org/vigibase/vigibase/
Uppsala Monitoring Centre. "VigiAccess." https://vigibase.who-umc.org
Lindquist M. "VigiBase, the WHO Global ICSR Database System: Basic Facts." Drug Information Journal. 2008;42(5):409-419. https://doi.org/10.1177/009286150804200501
WHO. "The WHO Programme for International Drug Monitoring." World Health Organization. https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/who-programme-for-international-drug-monitoring